Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

German stocks rose in early trade on Wednesday, extending gains after finishing at a record amid signs that interest rates will fall in both Europe and the U.S.

German stocks rise after ending at a record high

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced that its two Phase III EVOLUTION clinical trials (evolutionRMS 1 and evolutionRMS 2) investigating the efficacy and safety of evobrutinib did not meet their primary endpoints of reducing annualized relapse rates (ARR) in people with relapsing multiple sclerosis (RMS) compared to oral teriflunomide (0.11 vs. 0.11 in evolutionRMS 1 and 0.15 for evobrutinib and 0.14 for teriflunomide in evolutionR.

Merck Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis

Fastenal

McCormick

NIKE

PulteGroup

Dividend growth stocks consistently increase their dividend year after year with a 5-year growth rate of 10% or more. Companies must generate strong free cash flow to sustain dividend growth. All 5 of these stocks have recently increased their dividend, with the largest increase being as high as 25%.

5 Stocks That Recently Increased Their Dividend

SHANGHAI , Dec. 4, 2023 /PRNewswire/ -- On 4 Dec. 2023, Abbisko Therapeutics announced that it has entered into a licensing agreement with Merck, a leading science and technology company headquartered in Darmstadt, Germany. Under the terms of the agreement, Merck will be granted an exclusive license to commercialize products comprising or containing pimicotinib (ABSK021) for all indications in Chinese mainland, Hong Kong, Macau and Taiwan (the "Licensed Territory"), and Abbisko Therapeutics will retain the exclusive rights to develop pimicotinib within the Licensed Territory.

Abbisko Therapeutics Announced the Entry into a Licensing Agreement for Pimicotinib (ABSK021) with Merck

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced a license agreement with Abbisko Therapeutics Co. Ltd., Shanghai, China, for pimicotinib (ABSK021), which is currently being evaluated in a Phase III study for the treatment of tenosynovial giant cell tumor (TGCT). TGCT is a benign tumor of the joints that can cause swelling, pain, stiffness, and limited mobility of the affected joints. Treatment options for this disease, which can seriously af.

Merck Strengthens Oncology Portfolio Through Commercialization Agreement With Abbisko for Phase III Asset, Pimicotinib

Amgen

Cisco Systems

Chevron

Dow Inc

Goldman Sachs

Johnson & Johnson

Coca-Cola

Verizon

Walgreens

Walmart

"The Dow [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation is also a consideration.” – Dow Jones & Co. The highest-yield 10 stocks are December's Dogs of the Dow: KO, AMGN, CSCO, GS, IBM, CVX, DOW, MMM, VZ, and WBA. They only averaged a 4.92% annual yield, as December prices rose. Thirty Dow stocks represent nine of eleven sectors. Dow Jones tracks utilities as a separate index and omits real estate. Broker top-ten target-estimated December net gains ranged between 11.08%-44.04%, topped by WBA 11/30/23.

December Dogs Of The Dow: 3 Buyable, 5 Watchable

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Grants Priority Review to Merck's Application for KEYTRUDA Plus Padcev for the First-Line Treatment of Patients With Advanced Urothelial Cancer.

FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer

Apartment Income REIT Corp

Alexandria Real Estate Equities

AstraZeneca

COPT Defense Properties

Gilead Sciences

Gaming and Leisure Properties

Healthcare Realty Trust Inc

Host Hotels & Resorts

Johnson Controls

LTC Properties

Banco Santander

Sabra Health Care

Telia Co AB

V.F.

Vici Properties

Telefonica Brasil

September-October, 2023, Barron's, Bloomberg, and Fortune analysts and reporters combined to list five sets of stocks sorted as “Recovery Bets.” Those five articles revealed 53 equities, with 42 paying-dividends. These recovery lists focus on financial services, healthcare, and real estate sectors by Barron's along with selected “change the world” stocks from Fortune and ten to watch from Bloomberg.

17 Ideal Pre-Crash Recovery December Divi-Dogs

Merck & Co., Inc. (NYSE:MRK ) 6th Annual Evercore ISI HealthCONx Conference Transcript November 30, 2023 1:20 PM ET Executives Dr. Eliav Barr - Senior Vice President, Head, Global Clinical Development and CMO Peter Dannenbaum - Vice President, Investor Relations Analysts Umer Raffat - Evercore Umer Raffat Thank you. Listen, thank you guys for being here.

Merck & Co., Inc. (MRK) Management Presents at 6th Annual Evercore ISI HealthCONx Conference (Transcript)

Positive data from Merck's (MRK) phase III study on V116, an investigational, 21-valent pneumococcal conjugate vaccine, supports the immunogenicity of V116 compared to standard of care.

Merck's (MRK) Pneumococcal Jab Shows Upbeat Responses in Study

Merck & Co. Inc. MRK said Tuesday its board has raised its quarterly dividend to 77 cents. The dividend was previously 73 cents.

Merck raises quarterly dividend to 77 cents vs. 73 cents

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces First-Quarter 2024 Dividend.

Merck Announces First-Quarter 2024 Dividend

Digital Realty Trust

Estee Lauder

Paramount Global

Pfizer

Stanley Black & Decker

Tyson Foods

It's only November — but if you're like most investors — 2024 is what matters now. And some S&P 500 companies already look primed to put up big numbers.

7 Companies Will Propel Profit More Than 100% Next Year: Analysts

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck's V116 an Investigational 21-valent PCV Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV20 in Adults 50+.

Merck's V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults, Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV20 in Adults 50 Years of Age and Older

Duke Energy

Hershey

Kellogg

Procter & Gamble

Safety Insurance

At first blush, focusing on low-volatility stocks may appear an overly pessimistic strategy. After all, the benchmark S&P 500 gained almost 8% in the trailing month.

Stability Seekers: 7 Low-Volatility Stocks for Uncertain Times

Merck is a legacy drugmaker with a history of fat margins and occasional robust growth. The company is entering a new growth phase, making it a good investment opportunity. Merck has a low forward P/E ratio and strong growth prospects, making it suitable for retirees and investors approaching retirement.

Merck Will Keep Your Retirement Income Healthy

Merck (MRK) has been a shareholder in Caraway Therapeutics since 2018 through its MRL Ventures Fund.

Merck (MRK) to Acquire Private Neuroscience Company for $610M

Merck & Co Inc announced on Tuesday an agreement to acquire Caraway Therapeutics Inc for a total potential consideration of up to $610 million, including an undisclosed upfront payment and earnout milestones linked to the development of certain drugs Caraway has in the pipeline.  Caraway, a drug developer, has a drug pipeline that includes experimental treatment of genetically defined neurodegenerative and rare diseases, such as Parkinson's disease.

Merck to acquire Caraway Therapeutics for up to $610M

Merck & Co. Inc. MRK said Tuesday it agreed to pay up to $610 million to acquire Caraway Therapeutics, a preclinical biopharmaceutical company pursuing new approaches for the treatment of genetically defined neurodegenerative and rare diseases. The company's pipeline includes novel, small-molecule therapeutics for the treatment of genetically defined neurodegenerative and rare diseases.

Merck paying $610 million for Caraway Therapeutics

Merck reported positive quarterly earnings with 6.7% year-over-year revenue growth and improved operating margin. The company generated strong leveraged free cash flow and reduced financial leverage, improving its net debt position. Merck has raised dividends for 12 consecutive years with an average growth rate nearing 10%.

Merck: A Dividend Growth Stock Worth Considering

Apple

Amazon

Boeing

Bank of America

Alphabet

JPMorgan Chase & Co

Marathon Petroleum

Microsoft

Micron Technology

NVIDIA

Tesla

Valero Energy

Wells Fargo

In a simple world, the stock market is never more than earnings and the multiple investors assign to them.

These ten stocks, not just from tech, are the key to next year's S&P 500 earnings growth

News for Merck Stock (MRK)